Acceleration of α-synuclein aggregation by homologous peptides

FEBS Letters

Volumn 580, Issue 15, 2006, Pages 3657-3664

  Du, Hai Ning ^a   Li, Hong Tao ^a   Zhang, Feng ^b   Lin, Xiao Jing ^a   Shi, Jia Hao ^a   Shi, Yan Hong ^c   Ji, Li Na ^b   Hu, Jun ^b   Lin, Dong Hai ^c   Hu, Hong Yu ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Synuclein; Aggregation; Fibrillization; GAV motif; Homologous peptide; Parkinson's disease

Indexed keywords

ALANINE; ALPHA SYNUCLEIN; GLYCINE; PEPTIDE DERIVATIVE; VALINE;

ACCELERATION; AMINO ACID SEQUENCE; ARTICLE; FIBER; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN STABILITY; SEQUENCE HOMOLOGY; WILD TYPE;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; CIRCULAR DICHROISM; GLYCINE; HUMANS; MICROSCOPY, ATOMIC FORCE; MUTATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 33745121493     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.05.050     Document Type: Article

References (33)

1. Koo E.H., Lansbury P.T., and Kelly J.W. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 96 (1999) 9989-9990
2. Temussi P.A., Masino L., and Pastore A. From Alzheimer to Huntington: Why is a structural understanding so difficult?. EMBO J. 22 (2003) 355-361
3. Dickson D.W. Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol. 14 (2001) 423-432
4. Conway K.A., Harper J.D., and Lansbury P.T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39 (2000) 2552-2563
5. Harper J.D., and Lansbury P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66 (1997) 385-407
6. Prusiner S.B. Molecular biology and pathogenesis of prion diseases. Trends Biochem. Sci. 21 (1996) 482-487
7. Han H., Weinreb P.H., and Lansbury P.T. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?. Chem. Biol. 2 (1995) 163-169
8. El-Agnaf O.M., Bodles A.M., Guthrie D.J.S., Harriott P., and Irvine G.B. The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur. J. Biochem. 258 (1998) 157-163
9. Hu H.Y. Abnormal protein aggregation and neurodegenerative diseases. Chin. Sci. Bull. 46 (2001) 1-3
10. DeMarco M.L., and Daggett V. From conversion to aggregation: protofibril formation of the prion protein. Proc. Natl. Acad. Sci. USA 101 (2004) 2293-2298
11. Florio T., Paludi D., Villa V., Principe D.R., Corsaro A., Millo E., Damonte G., D'Arrigo C., Russo C., Schettini G., and Aceto A. Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic. J. Neurochem. 85 (2003) 62-72
12. Tjernberg L.O., Callaway D.J.E., Tjernberg A., Hahnet S., Lilliehook C., Terenius L., Thyberg J., and Nordstedt C. A molecular model of Alzheimer amyloid beta-peptide fibril formation. J. Biol. Chem. 274 (1999) 12619-12625
13. Balbach J.J., Ishii Y., Antzutkin O.N., Leapman R.D., Rizzo N.W., Dyda F., Reed J., and Tycko R. Amyloid fibril formation by Aβ16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR. Biochemistry 39 (2000) 13748-13759
14. Jarrett J.T., Berger E.P., and Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
15. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., and Lansbury P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996) 13709-13715
16. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97 (2000) 571-576
17. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
18. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95 (1998) 6469-6473
19. Miake H., Mizusawa H., Iwatsubo T., and Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 277 (2002) 19213-19219
20. Bodles A.M., Guthrie D.J.S., Greer B., and Irvine G.B. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 78 (2001) 384-395
21. Du H.N., Tang L., Luo X.Y., Li H.T., Hu J., Zhou J.W., and Hu H.Y. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry 42 (2003) 8870-8878
22. Uversky V.N., and Fink A.L. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 522 (2002) 9-13
23. Hu H.Y., Li Q., Cheng H.C., and Du H.N. Beta-sheet structure formation of proteins in solid state as revealed by circular dichroism spectroscopy. Biopolymer 62 (2001) 15-21
24. Li H.T., Du H.N., Tang L., Hu J., and Hu H.Y. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation. Biopolymers 64 (2002) 221-226
25. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309 (1999) 274-284
26. Li H.T., Lin D.H., Luo X.Y., Zhang F., Ji L.N., Du H.N., Song G.Q., Hu J., Zhou J.W., and Hu H.Y. Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino groups of α-synuclein: implication for dopaminergic neurodegeneration. FEBS J. 272 (2005) 3661-3672
27. Ji L.N., Du H.N., Zhang F., Li H.T., Luo X.Y., Hu J., and Hu H.Y. An unstructured region is required by GAV homologue for the fibrillization of host proteins. Protein J. 24 (2005) 209-218
28. Pawar A.P., Dubay K.F., Zurdo J., Chiti F., Vendruscolo M., and Dobson C.M. Prediction of "aggregation-prone" and aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350 (2005) 379-392
29. El-Agnaf O.M., Paleologou K.E., Greer B., Abogrein A.M., King J.E., Salem S.A., Fullwood N.J., Benson F.E., Hewitt R., Ford K.J., Martin F.L., Harriott P., Cookson M.R., and Allsop D. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18 (2004) 1315-1317
30. Silveira J.R., Raymond G.J., Hughson A.G., Race R.E., Sim V.L., Hayes S.F., and Caughey B. The most infectious prion protein particles. Nature 437 (2005) 257-261
31. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F., Kascsak R., Mendez E., Harris D.A., Ironside J., Tagliavini F., Carp R.I., and Frangione B. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 355 (2000) 192-197
32. Kapurniotu A., Schmauder A., and Tenidis K. Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J. Mol. Biol. 315 (2002) 339-350
33. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., Dewachter I., Banks W.A., Van Leuven F., and Soto C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with β-sheet breaker peptide. FASEB J. 8 (2002) 860-862